ViGenCell

ViGenCell EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ViGenCell (308080.KQ) as of Oct 19, 2026 is -17.11 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -14.49 B KRW — a change of 18.10% (lower).

EBITDA

-17.11 BKRW

YoY

18.10%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ViGenCell is 2025 -17.11 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ViGenCell was 2024 -14.49 B KRW. It decreases by 18.10% lower compared to the previous year.

The ViGenCell EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-15.04 B KRW
Jan 1, 2020
-7.51 B KRW
Jan 1, 2021
-12.20 B KRW
Jan 1, 2022
-18.21 B KRW
Jan 1, 2023
-18.99 B KRW
Jan 1, 2024
-14.49 B KRW
Jan 1, 2025
-17.11 B KRW
The ViGenCell EBITDA history
YEAREBITDAYoY
-17.11 BKRW+18.10%
-14.49 BKRW-23.73%
-18.99 BKRW+4.28%
-18.21 BKRW+49.31%
-12.20 BKRW+62.45%
-7.51 BKRW-50.06%
-15.04 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViGenCell Stock analysis

What does ViGenCell do? ViGenCell Inc is a biotechnology company based in Seoul, South Korea, operating within the Health Care sector. The company has 80 employees and completed its initial public offering (IPO) on August 25, 2021. ViGenCell focuses on research and development in natural science and engineering, with a particular emphasis on cell therapy technologies. The company develops and manufactures immuno-cancer cell therapy products and immunosuppressive cell therapy products. It also provides the Vitier platform, which is an antigen-specific killing T cell treatment, the Viranger platform for gamma delta T cell gene therapy, and the Vimedier platform-based technology for myeloid suppressor cell therapy derived from umbilical cord blood. ViGenCell is engaged in the research and development of new drugs targeting conditions such as acute myeloid leukemia (AML) and glioblastoma. The company's website is https://www.vigencell.com/. ViGenCell Inc is listed on the Korean stock market under the ticker 308080.KQ and has the ISIN KR7308080001. The company's headquarters are located in Seoul, South Korea. ViGenCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViGenCell stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ViGenCell is -17.11 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ViGenCell changed from -14.49 B KRW to -17.11 B KRW, representing a 18.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ViGenCell since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ViGenCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ViGenCell

All Key Metrics — ViGenCell